Abstract
Amineh Khoshnazar, Ameneh Koochaki, Sara Anajafi, Yalda Khazaei-Poul, Hossein Ghanbarian, Samira Mohammadi‐Yeganeh, Mahdi Paryan, Vahid Haghpanah
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Trends in incidence, metastasis, and mortality from thyroid cancer in the USA from 1975 to 2019: a population-based study of age, period, and cohort effects
10.1016/s2213-8587(24)00310-3 · 2025
Anaplastic thyroid carcinoma: an update
10.3390/cancers14041061 · 2022
Mechanisms of angiogenesis in tumour
2024
Targeting the tumour vasculature: from vessel destruction to promotion
10.1038/s41568-024-00736-0 · 2024
The roles and role-players in thyroid cancer angiogenesis
10.1507/endocrj.ej18-0537 · 2019
Tumor angiogenesis and anti-angiogenic therapy
10.1097/cm9.0000000000003231 · 2024
NFκB-Mediated mechanisms drive PEDF expression and function in pre- and post-menopausal oestrogen levels in breast cancer
10.3390/ijms232415641 · 2022
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
10.1038/s41392-023-01460-1 · 2023
Pigment epithelium-derived factor (PEDF), a serpin with potent anti-angiogenic and neurite outgrowth-promoting properties
10.1515/bc.2002.188 · 2002
PEDF inhibits lymphatic metastasis of nasopharyngeal carcinoma as a new lymphangiogenesis inhibitor
10.1038/s41419-021-03583-1 · 2021
The role of PEDF, VEGF, and Ki-67 in tissue invasion and tumor angiogenesis of medullary thyroid carcinoma
10.32552/2023.actamedica.974 · 2023
Overexpression of pigment epithelium-derived factor in breast cancer cell-derived exosomes induces M1 polarization in macrophages
10.1016/j.imlet.2022.05.005 · 2022
VEGF in signaling and disease: beyond discovery and development
10.1016/j.cell.2019.01.021 · 2019
Angiogenesis-inhibitors for metastatic thyroid cancer
2010
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method
10.1006/meth.2001.1262 · 2001
Alkaloid extract of Corydalis yanhusuo inhibits angiogenesis via targeting vascular endothelial growth factor receptor signaling
10.1186/s12906-019-2739-6 · 2019
2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer
10.1089/thy.2020.0944 · 2021
Update on current diagnosis and management of anaplastic thyroid carcinoma
10.5306/wjco.v14.i12.570 · 2023
The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential
10.1038/nrc3484 · 2013
Assessment of AXL and mTOR genes expression in medullary thyroid carcinoma (MTC) cell line in relation with over expression of miR-144 and miR-34a
10.1515/hmbci-2020-0050 · 2021
Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC
10.1016/j.humpath.2018.05.019 · 2018
An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients
10.1002/jcp.29055 · 2020
PEDF-induced alteration of metabolism leading to insulin resistance
10.1016/j.mce.2014.11.006 · 2015
PEDF inhibits non‑small cell lung cancer proliferation by suppressing autophagy through downregulation of AMPK‑ULK1 signaling
10.3892/or.2022.8434 · 2022
Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors
10.1007/s00432-024-05714-5 · 2024
Prognostic and therapeutic role of angiogenic microenvironment in thyroid cancer
10.3390/cancers13112775 · 2021
PEDF is an endogenous inhibitor of VEGF-R2 angiogenesis signaling in endothelial cells
10.1016/j.exer.2021.108828 · 2021
Pigment epithelium‑derived factor has a role in the progression of papillary thyroid carcinoma by affecting the HIF1α‑VEGF signaling pathway
10.3892/ol.2016.5316 · 2016
The novel oncogenic factor TET3 combines with AHR to promote thyroid cancer lymphangiogenesis via the HIF-1α/VEGF signaling pathway
10.1186/s12935-023-03021-6 · 2023
Characterization of PEDF: a multi-functional serpin family protein
10.1002/jcb.22072 · 2009
Adenovirus-mediated PEDF expression inhibits prostate cancer cell growth and results in augmented expression of PAI-2
10.4161/cbt.6.3.3757 · 2007
Inhibitory effects of pigment epithelium-derived factor on epithelial-mesenchymal transition, migration and invasion of breast cancer
2017
The contrary intracellular and extracellular functions of PEDF in HCC development
10.1038/s41419-019-1976-4 · 2019
Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo
10.1016/s0002-9440(10)63210-5 · 2004
Pigment epithelium-derived factor (PEDF) inhibits survival and proliferation of VEGF-exposed multiple myeloma cells through its anti-oxidative properties
10.1016/j.bbrc.2013.01.057 · 2013
Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells
10.1016/j.lfs.2005.05.048 · 2005
Evaluation of protein pigment epithelium-derived factor (PEDF) and microvessel density (MVD) as prognostic indicators in breast cancer
10.1007/s00432-010-0830-y · 2010
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer
10.1016/j.ctrv.2016.03.004 · 2016
Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma
10.1089/thy.2018.0060 · 2018
Lenvatinib as a novel treatment for anaplastic thyroid cancer: a retrospective study
2018
Molecular diagnostics and predictors in thyroid cancer
10.1089/thy.2009.0240 · doi-reference
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies
10.1158/1078-0432.ccr-18-2953 · doi-reference
Anti-inflammatory properties of pigment epithelium-derived factor
10.1177/1721727x221138857 · doi-reference
Development and safety of PI3K inhibitors in cancer
10.1007/s00204-023-03440-4 · doi-reference